APRE ▲ +8.2% - Aprea Therapeutics, Inc. $APRE - Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona 20-NOV-2026 09:00 AM ET